JP2023531970A5 - - Google Patents

Info

Publication number
JP2023531970A5
JP2023531970A5 JP2022579736A JP2022579736A JP2023531970A5 JP 2023531970 A5 JP2023531970 A5 JP 2023531970A5 JP 2022579736 A JP2022579736 A JP 2022579736A JP 2022579736 A JP2022579736 A JP 2022579736A JP 2023531970 A5 JP2023531970 A5 JP 2023531970A5
Authority
JP
Japan
Prior art keywords
composition according
group
cancer
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022579736A
Other languages
English (en)
Japanese (ja)
Other versions
JP7804596B2 (ja
JP2023531970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038339 external-priority patent/WO2021262627A1/en
Publication of JP2023531970A publication Critical patent/JP2023531970A/ja
Publication of JP2023531970A5 publication Critical patent/JP2023531970A5/ja
Application granted granted Critical
Publication of JP7804596B2 publication Critical patent/JP7804596B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022579736A 2020-06-23 2021-06-22 ヘテロアリール-ビフェニルアミド誘導体を用いて癌を処置する方法 Active JP7804596B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042807P 2020-06-23 2020-06-23
US63/042,807 2020-06-23
PCT/US2021/038339 WO2021262627A1 (en) 2020-06-23 2021-06-22 Methods of treating cancer using heteroaryl-biphenyl amide derivatives

Publications (3)

Publication Number Publication Date
JP2023531970A JP2023531970A (ja) 2023-07-26
JP2023531970A5 true JP2023531970A5 (cg-RX-API-DMAC7.html) 2024-06-07
JP7804596B2 JP7804596B2 (ja) 2026-01-22

Family

ID=79022859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579736A Active JP7804596B2 (ja) 2020-06-23 2021-06-22 ヘテロアリール-ビフェニルアミド誘導体を用いて癌を処置する方法

Country Status (14)

Country Link
US (3) US20210393759A1 (cg-RX-API-DMAC7.html)
EP (1) EP4167991A4 (cg-RX-API-DMAC7.html)
JP (1) JP7804596B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230040993A (cg-RX-API-DMAC7.html)
CN (1) CN116472045B (cg-RX-API-DMAC7.html)
AU (1) AU2021297216B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022026397A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187605A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003716A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000703A2 (cg-RX-API-DMAC7.html)
IL (1) IL299206A (cg-RX-API-DMAC7.html)
MX (1) MX2022016554A (cg-RX-API-DMAC7.html)
TW (1) TW202216694A (cg-RX-API-DMAC7.html)
WO (1) WO2021262627A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102670486B1 (ko) 2017-08-08 2024-05-28 케모센트릭스, 인크. 마크로사이클릭 면역조절제
WO2019165043A2 (en) 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
ES3068390T3 (en) * 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673919B2 (en) * 2009-03-27 2014-03-18 Ardea Biosciences, Inc. Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors
EA023521B1 (ru) * 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
US10308644B2 (en) * 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
CN106674136B (zh) * 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
US10919852B2 (en) * 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
EP3735410A4 (en) * 2017-10-19 2021-11-03 Tempest Therapeutics, Inc. PICOLINAMIDE COMPOUNDS
WO2019160882A1 (en) * 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019165043A2 (en) * 2018-02-22 2019-08-29 Chemocentryx, Inc. Indane-amines as pd-l1 antagonists
BR112021022659A2 (pt) * 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
ES3068390T3 (en) * 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases

Similar Documents

Publication Publication Date Title
CN114761411B (zh) 作为erk抑制剂的螺环类化合物及其应用
JP2025023997A (ja) Fak阻害剤およびその併用薬物
JP2023533938A5 (cg-RX-API-DMAC7.html)
JP2023040165A5 (cg-RX-API-DMAC7.html)
US11685757B2 (en) Pharmaceutical co-crystal composition and use thereof
KR20180017013A (ko) K-Ras 조절제
US12030897B2 (en) Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof
JP2023531709A5 (cg-RX-API-DMAC7.html)
RU2018129344A (ru) Производное хиназолинона, способ его получения, фармацевтическая композиция и применения
JP2023548204A (ja) Cd73阻害剤及びその応用
US12448378B2 (en) Fluoropyrrolopyridine compound and application thereof
JP2022506059A5 (cg-RX-API-DMAC7.html)
CN110357885A (zh) 一种蝶啶类化合物及其在药学上的应用
CA2797182A1 (en) Methods of enhancing antibody-dependent cellular cytotoxicity
CN113825755A (zh) 作为irak4抑制剂的咪唑并吡啶类化合物
JP7331116B2 (ja) TGF-βR1キナーゼ阻害剤としての5-(4-ピリジルオキシ)ピラゾール類化合物
US11066421B1 (en) Synthetic cinchona alkaloids against cancer
JP2008516989A (ja) 組成物及び抗腫瘍剤としてのその使用
CN110845408A (zh) 同位素富集的乐伐替尼
US10556875B2 (en) Bis-diazeniumdiolate compounds as anti-cancer agents
JP2024538128A5 (cg-RX-API-DMAC7.html)
RU2011136855A (ru) Производные бензотиазолов и бензимидазолов, содержащие 6-nh-замещенные триазолопиридазинсульфанил в положении 6: получение, применение в качестве лекарственных средств и применение в качестве ингибиторов мет
JP2023547954A5 (cg-RX-API-DMAC7.html)
CN105209032A (zh) 使用转录因子调节剂治疗癌症和其他病症
JP2022512874A5 (cg-RX-API-DMAC7.html)